Phase 3 Start
NVO: Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
September 22, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 22, 2026
- Company
- Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Start
Phase3_Start: Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)
- Company
- Novo Nordisk A/S (NVO)